Revlimid (Lenalidomide) (25 Milligram, Capsules)


Indications and Reactions:

Role Indications Reactions
Primary
Plasma Cell Myeloma 94.0%
Product Used For Unknown Indication 1.8%
Lymphoma 0.8%
Multiple Myeloma 0.7%
Amyloidosis 0.3%
Hodgkin's Disease 0.3%
Myelodysplastic Syndrome 0.3%
Non-hodgkin's Lymphoma 0.3%
Malignant Lymphoid Neoplasm 0.2%
Myeloid Leukaemia 0.2%
Plasmacytoma 0.2%
Acute Myeloid Leukaemia 0.1%
Alanine Aminotransferase Increased 0.1%
Anaplastic Large Cell Lymphoma T- And Null-cell Types 0.1%
Chronic Leukaemia 0.1%
Chronic Lymphocytic Leukaemia 0.1%
Diffuse Large B-cell Lymphoma 0.1%
Fibrosarcoma 0.1%
Gout 0.1%
Hodgkin's Disease Refractory 0.1%
Thrombosis 12.3%
Pneumonia 9.7%
Plasma Cell Myeloma 9.3%
White Blood Cell Count Decreased 8.9%
Rash 8.2%
Drug Dose Omission 5.8%
Fatigue 5.0%
Pancytopenia 4.8%
Platelet Count Decreased 4.5%
Full Blood Count Decreased 3.9%
Vomiting 3.7%
Pyrexia 3.0%
Weight Decreased 3.0%
Deep Vein Thrombosis 2.8%
Neuropathy Peripheral 2.8%
Neutropenia 2.6%
Pulmonary Embolism 2.6%
Diarrhoea 2.4%
Rash Generalised 2.4%
Muscle Spasms 2.2%
Secondary
Plasma Cell Myeloma 100.0%
Neuropathy Peripheral 50.0%
Rash 50.0%

Drug Data